Geron has received FDA approval for its drug RYTELO to treat low- to intermediate-1 risk myelodysplastic syndromes (MDS), a significant achievement after years of development. Although initial sales of RYTELO have been disappointing, Geron projects revenues between $220 million and $240 million by 2026 and is focusing on commercial growth and expansion into Europe. The company has a new management team, strong liquidity with $341 million in cash, and about 2.7 years of financial runway to support ongoing development and marketing efforts. Key risks include heavy dependence on RYTELO, competition from Bristol-Myers Squibb's Reblozyl, and potential dilution if sales do not improve.
Taiwan Semiconductor Manufacturing Company (TSMC) reported a 23.4% increase in second-quarter profit from the previous quarter, surpassing analyst estimates. The company's net income reached NT$706.56 billion ($39.45 billion), a record high for the f...
National Beverage faces stagnant growth as LaCroix volumes have declined for four straight years, reducing brand excitement. The stock trades at reasonable multiples reflecting muted growth and no clear catalysts for upside. Despite stable gross marg...
Arthur Hayes reversed his crypto strategy by purchasing over $3.7 million worth of Ethereum after selling 6,000 ETH at a loss of about $606,000 just weeks prior. This move follows his pattern of bold crypto trades and quick exits, which have drawn cr...
A bitcoin wallet that had been inactive since 2017 moved its entire holding of 5,908 BTC, now worth about $383 million, to a new, unidentified address. The coins were originally bought near bitcoin's 2017 peak at around $16,000 each and have gained r...
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
